CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-06 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +3,970 | $12.65 | $50K | 7,592 |
| 2026-04-06 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −3,970 | $18.01 | $72K | 3,622 |
| 2026-04-06 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,970 | 210,530 | ||
| 2026-04-02 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −6,200 | $17.02 | $106K | 19,118 |
| 2026-04-02 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −1,780 | $17.57 | $31K | 17,338 |
| 2026-04-01 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +679 | $8.04 | $5K | 4,301 |
| 2026-04-01 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −679 | $16.00 | $11K | 3,622 |
| 2026-04-01 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −679 | 148,329 | ||
| 2026-04-01 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −500 | $15.86 | $8K | 32,797 |
| 2026-04-01 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −7,479 | $16.83 | $126K | 25,318 |
| 2026-03-31 | Jain Rita Director | Grant or award · Stock Option (Right to Buy) | +1,339 | $12.13 | $16K | 1,339 |
| 2026-03-31 | Lind Kevin Robert Director | Grant or award · Stock Option (Right to Buy) | +1,370 | $12.13 | $17K | 1,370 |
| 2026-03-28 | Truex Samantha Director | Option exercise | +3,166 | 6,333 | ||
| 2026-03-28 | Truex Samantha Director | Option exercise · Restricted Stock Units | −3,166 | 3,167 | ||
| 2026-03-28 | Goldman Jonathan Director | Option exercise | +3,166 | 3,166 | ||
| 2026-03-28 | Goldman Jonathan Director | Option exercise · Restricted Stock Units | −3,166 | 3,167 | ||
| 2026-03-28 | KANTOFF AARON Director | Option exercise | +3,166 | 6,333 | ||
| 2026-03-28 | KANTOFF AARON Director | Option exercise · Restricted Stock Units | −3,166 | 3,167 | ||
| 2026-03-28 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise | +24,200 | 41,538 | ||
| 2026-03-28 | Sullivan Christopher Ryan Chief Financial Officer | Shares withheld for taxes | −8,241 | $13.89 | $114K | 33,297 |
Page 6 of 11 · 202 trades